# IDRX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/idrx

- Industry: Biotechnology
- Headquarters: Plymouth, US
- Website: www.idrx.com/
- Total disclosed funding: $242M
- Latest round: Series B (Aug 7, 2024)
- Investors on record: 9

## About

IDRX, Inc. is a US-based biotechnology firm specializing in innovative treatments for gastrointestinal cancers, focusing on enhancing patient care through advanced therapeutic solutions.IDRX, Inc. is dedicated to developing groundbreaking therapies for gastrointestinal cancer. Founded in 2022 in Plymouth, US, the company has successfully completed 3 deals. The firm was co-founded by Alexis Borisy and Ben Auspitz, who has a background in founding other notable companies. The company recently secured a TRADE SALE funding round, raising a total amount of USD 1 billion from GlaxoSmithKline Plc, effectively marking its total funds raised at USD 1 billion. The most recent deal occurred on January 13, 2025.IDRX, Inc. focuses on creating cutting-edge pharmaceutical products aimed at treating gastrointestinal cancers. Their innovative solutions target significant health challenges and are designed to improve patient outcomes. IDRX aims to make these therapies accessible to healthcare providers, hospitals, and patients across various regions, including North America, Europe, Asia, and Africa.The revenue for IDRX stems from its product offerings in the pharmaceutical sector, primarily through sales to healthcare providers and partnerships with distributors. The company establishes pricing structures that reflect the therapeutic area while emphasizing accessibility for diverse markets, particularly for chronic and infectious diseases associated with gastrointestinal cancers.In January 2025, GlaxoSmithKline Plc fully acquired IDRX, Inc. for USD 1 billion, with an additional USD 150 million allocated for milestone payments. This acquisition will enhance GSK's gastrointestinal cancer portfolio, supporting the launch of new therapeutic solutions. The company plans to leverage this funding to expand its market reach globally, particularly focusing on North America and Europe by the end of 2025.

## Funding rounds

- Series B, Aug 7, 2024, $120M — Nextech, Andreessen Horowitz, Casdin Capital, RA Capital Management, Rock Springs Capital, Blackstone Multi-Asset Advisors, Commodore Capital, Forge Life Science Partners
- Series A, May 10, 2022, $122M — Nextech, Andreessen Horowitz, Casdin Capital, Evrys Bio, Forge Life Science Partners

## Investors

- Nextech (https://capitalatlas.ai/funds/nextech) — Series A, Series B
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A, Series B
- Evrys Bio — Series A
- Forge Life Science Partners (https://capitalatlas.ai/funds/forge-life-science-partners) — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Rock Springs Capital — Series B
- Blackstone Multi-Asset Advisors (https://capitalatlas.ai/funds/blackstone-multi-asset-advisors) — Series B
- Commodore Capital (https://capitalatlas.ai/funds/commodore-capital) — Series B